We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Personalized CtDNA Analysis Detects Minimal Residual Disease

By LabMedica International staff writers
Posted on 08 Jun 2021
Print article
Image: Bone marrow aspirate showing mature plasma cells with eccentric nuclei and abundant basophilic cytoplasm indicative of multiple myeloma (Photo courtesy of Dr. David Israel Garrido, MD et.al.)
Image: Bone marrow aspirate showing mature plasma cells with eccentric nuclei and abundant basophilic cytoplasm indicative of multiple myeloma (Photo courtesy of Dr. David Israel Garrido, MD et.al.)
Multiple myeloma (MM), is a type of bone marrow cancer. It is called multiple myeloma as the cancer often affects several areas of the body, such as the spine, skull, pelvis and ribs. Minimal residual disease (MRD) is the name given to small numbers of leukemic cells that remain in the person during treatment, or after treatment when the patient is in remission.

Despite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), MM patients invariably relapse. MRD-negativity post-AHCT has emerged as the most important prognostic marker. Currently, MRD in MM is monitored via bone marrow aspirate sampling. Marrow MRD assays are limited by the spatial heterogeneity of marrow MM localization; extramedullary disease and sampling variability of marrow aspiration.

Hematologists at the Medical College of Wisconsin (Milwaukee, WI, USA) and their colleagues, analyzed in a retrospective, single-center study, circulating tumor DNA (ctDNA) MRD in blood samples collected from 28 patients with MM after upfront AHCT. A total of 80 plasma time points were available pre and post AHCT with a median follow-up of 92.4 months. Multiparameter flow cytometry (MFC) at 10-4 level was used to assess the MRD from the BM biopsy.

Individual bone marrow aspirates or Formalin-fixed, Paraffin-embedded (FFPE) slides from the time of MM diagnosis and matched normal blood were whole-exome sequenced, and somatic mutations were identified. MRD assessment at three months post-AHCT was performed by ctDNA analysis using a personalized, tumor-informed Signatera bespoke mPCR NGS assay (Natera Inc, San Carlos, CA, USA). The prognostic value of ctDNA was evaluated by correlating MRD status with clinical outcomes.

The scientists reported that ctDNA was detectable in 17/24 (70.8%) of pre-AHCT, 15/28 (53.6%) of ̃three months post-AHCT, and 11/28 (39.2%) of patients during the surveillance phase post-AHCT. Of the 15 ctDNA MRD positive patients, 93.3% experienced relapse on follow-up (hazard ratio: 5.64). Patients negative for ctDNA at three months post-AHCT had significantly superior progression-free survival (PFS) compared to positive (median PFS, 84 months versus 31 months) The positive predictive value (PPV) for relapse among patients positive for ctDNA at three months post-AHCT was 93.3%, and significantly higher than marrow multiparametric flow cytometry (MFC) of 68.4%.

The authors concluded that their study shows the feasibility that a tumor-informed assay on archival blood samples is predictive of relapse post-AHCT. Future prospective studies with real-time marrow next generation sequencing (NGS) and ctDNA samples are needed to define the role of ctDNA in MM and its prognostic significance. The study was presented at the virtual 2021 ASCO Annual Meeting held June 4-8, 2021.

Related Links:
Medical College of Wisconsin
Natera Inc


Gold Supplier
SARS-CoV-2 S-IgG Antibody Assay
Lumipulse G SARS-CoV-2 S-IgG
New
Semi-Automated Coagulation Analyzer
Thrombo Fast+
New
Pancreatic Elastase ELISA Kit
Pancreatic Elastase ELISA
New
SARS-CoV-2 Antigen Immunofluorescence System
Watmind SARS-CoV-2 Antigen Immunofluorescence System

Print article

Channels

Immunology

view channel
Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)

Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers

Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing

The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.